Skip to main content

Dermatomyositis

9
Pipeline Programs
13
Companies
19
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
5
0
3
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
350%
Monoclonal Antibody
233%
Peptide
117%
+ 14 programs with unclassified modality

Competitive Landscape

13 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
4 programs
1
2
1
DazukibartPhase 31 trial
Anti-Beta InterferonPhase 21 trial
PF-06823859 lowPhase 21 trial
TofacitinibPhase 1Small Molecule1 trial
Active Trials
NCT03002649Completed10Est. Sep 2020
NCT05192200Completed24Est. Nov 2023
NCT03181893Completed75Est. Nov 2022
+1 more trials
Priovant Therapeutics
2 programs
1
1
BrepocitinibPhase 3Small Molecule1 trial
BrepocitinibPhase 2Small Molecule1 trial
Active Trials
NCT06433999Completed5Est. Feb 2025
NCT05437263Active Not Recruiting241Est. Jul 2026
CSL Seqirus
CSL SeqirusUK - Maidenhead
1 program
1
human immunoglobulin GPhase 3
ImmunoForge
ImmunoForgeKorea - Seoul
1 program
1
FroniglutidePhase 2Peptide1 trial
Active Trials
NCT05833711Unknown39Est. Sep 2025
Neovacs
NeovacsFrance - Suresnes
1 program
1
IFN-KinoidPhase 21 trial
Active Trials
NCT02980198Withdrawn0Est. Dec 2019
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
2 programs
Multi-modal photoacoustic/ultrasonicN/A1 trial
TocilizumabN/AMonoclonal Antibody1 trial
Active Trials
NCT07037472Recruiting100Est. Dec 2028
NCT07377058Recruiting110Est. Oct 2026
Corbus Pharmaceuticals
2 programs
JBT-101PHASE_21 trial
Lenabasum 20 mgPHASE_31 trial
Active Trials
NCT02466243Terminated22Est. Jan 2021
NCT03813160Completed176Est. Oct 2021
Octapharma
OctapharmaAustria - Vienna
2 programs
Octagam 10%PHASE_31 trial
OctanormPHASE_31 trial
Active Trials
NCT02728752Completed95Est. Nov 2019
NCT03686969Terminated1Est. Nov 2018
argenx
argenxBelgium - Zwijnaarde
1 program
Empasiprubart IVPHASE_21 trial
Active Trials
NCT06284954Active Not Recruiting3Est. Nov 2026
Galapagos
Galapagos2800 MECHELEN, Belgium
1 program
GLPG3667PHASE_21 trial
Active Trials
NCT05695950Active Not Recruiting40Est. Apr 2026
NovelMed Therapeutics
NovelMed TherapeuticsOH - Cleveland
1 program
NM8074PHASE_21 trial
Active Trials
NCT06887738Not Yet Recruiting8Est. Dec 2028
Genentech
GenentechCA - Oceanside
1 program
tocilizumabPHASE_2Monoclonal Antibody1 trial
Active Trials
NCT02043548Completed36Est. Jul 2019
CSL Behring
CSL BehringIL - Bradley
1 program
human immunoglobulin GPHASE_31 trial
Active Trials
NCT04044690Terminated134Est. Dec 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
PfizerDazukibart
Priovant TherapeuticsBrepocitinib
CSL Behringhuman immunoglobulin G
Corbus PharmaceuticalsLenabasum 20 mg
OctapharmaOctanorm
OctapharmaOctagam 10%
NovelMed TherapeuticsNM8074
Priovant TherapeuticsBrepocitinib
argenxEmpasiprubart IV
ImmunoForgeFroniglutide
GalapagosGLPG3667
PfizerAnti-Beta Interferon
PfizerPF-06823859 low
NeovacsIFN-Kinoid
Corbus PharmaceuticalsJBT-101

Showing 15 of 19 trials with date data

Clinical Trials (19)

Total enrollment: 1,330 patients across 19 trials

NCT06698796PfizerDazukibart

A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies

Start: Jan 2025Est. completion: Nov 2027211 patients
Phase 3Recruiting
NCT05437263Priovant TherapeuticsBrepocitinib

A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis

Start: Oct 2022Est. completion: Jul 2026241 patients
Phase 3Active Not Recruiting
NCT04044690CSL Behringhuman immunoglobulin G

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)

Start: Oct 2019Est. completion: Dec 2024134 patients
Phase 3Terminated
NCT03813160Corbus PharmaceuticalsLenabasum 20 mg

Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis

Start: Dec 2018Est. completion: Oct 2021176 patients
Phase 3Completed
NCT03686969OctapharmaOctanorm

Study Evaluating Efficacy and Safety of Octanorm in Patients With Dermatomyositis

Start: Aug 2018Est. completion: Nov 20181 patients
Phase 3Terminated
NCT02728752OctapharmaOctagam 10%

Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy)

Start: Feb 2017Est. completion: Nov 201995 patients
Phase 3Completed
NCT06887738NovelMed TherapeuticsNM8074

Study of NM8074 in Patients with Dermatomyositis (DM)

Start: Jun 2026Est. completion: Dec 20288 patients
Phase 2Not Yet Recruiting
NCT06433999Priovant TherapeuticsBrepocitinib

A 12-Week Open-Label Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Skin-Predominant Dermatomyositis

Start: Aug 2024Est. completion: Feb 20255 patients
Phase 2Completed
NCT06284954argenxEmpasiprubart IV

A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis

Start: Aug 2024Est. completion: Nov 20263 patients
Phase 2Active Not Recruiting
NCT05833711ImmunoForgeFroniglutide

Study Evaluating Efficacy and Safety of Froniglutide (PF1801) in Patients With Idiopathic Inflammatory Myopathy

Start: Sep 2023Est. completion: Sep 202539 patients
Phase 2Unknown
NCT05695950GalapagosGLPG3667

A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis

Start: Feb 2023Est. completion: Apr 202640 patients
Phase 2Active Not Recruiting
NCT05192200PfizerAnti-Beta Interferon

An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study

Start: Dec 2021Est. completion: Nov 202324 patients
Phase 2Completed
NCT03181893PfizerPF-06823859 low

A Study In Adults With Moderate To Severe Dermatomyositis

Start: Jan 2018Est. completion: Nov 202275 patients
Phase 2Completed
NCT02980198NeovacsIFN-Kinoid

Study of IFN-K in Dermatomyositis

Start: May 2017Est. completion: Dec 20190
Phase 2Withdrawn
NCT02466243Corbus PharmaceuticalsJBT-101

Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis

Start: Jun 2015Est. completion: Jan 202122 patients
Phase 2Terminated
NCT02043548Genentechtocilizumab

Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis

Start: Oct 2014Est. completion: Jul 201936 patients
Phase 2Completed
NCT03002649PfizerTofacitinib

Study of Tofacitinib in Refractory Dermatomyositis

Start: Jan 2017Est. completion: Sep 202010 patients
Phase 1Completed
NCT07377058UNION therapeuticsTocilizumab

RCT of Tocilizumab for Anti-MDA5+DM

Start: Nov 2025Est. completion: Oct 2026110 patients
N/ARecruiting
NCT07037472UNION therapeuticsMulti-modal photoacoustic/ultrasonic

Photoacoustic/Ultrasound Imaging in Patients of Dermatomyositis With Calcinosis Cutis: Characteristic Findings and Treatment Response Evaluation

Start: Jan 2024Est. completion: Dec 2028100 patients
N/ARecruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals
3 actively recruiting trials targeting 1,330 patients
13 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.